Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy

Technology appraisal guidance
Reference number: TA307
Published: 25 March 2014

History

Review proposal consultation

Review proposal consultation
Stakeholder matrix (PDF 99 KB)

Published:

22 August 2016
Review proposal paper (PDF 222 KB)

Published:

22 August 2016

Colorectal cancer (metastatic) - aflibercept: equality impact assessment form - guidance development

Colorectal cancer (metastatic) - aflibercept: equality impact assessment form - guidance development
Colorectal cancer (metastatic) - aflibercept: equality impact assessment form - guidance development (PDF 22 KB)

Published:

26 September 2014

Colorectal cancer (metastatic) - aflibercept: final appraisal determination

Colorectal cancer (metastatic) - aflibercept: final appraisal determination information
Colorectal cancer (metastatic) - aflibercept: final appraisal determination
Colorectal cancer (metastatic) - aflibercept: final appraisal determination (PDF 249 KB)

Published:

22 August 2014
Colorectal cancer (metastatic) - aflibercept: evaluation report information
Colorectal cancer (metastatic) - aflibercept: evaluation report (PDF 509 KB)

Published:

22 August 2014

Colorectal cancer (metastatic) - aflibercept: appeal

Colorectal cancer (metastatic) - aflibercept: appeal
Colorectal cancer (metastatic) - aflibercept: appeal decision
Colorectal cancer (metastatic) - aflibercept: appeal decision (PDF 280 KB)

Published:

21 March 2014
Colorectal cancer (metastatic) - aflibercept: appeal announcement information
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - appeal letter
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - appeal letter (PDF 893 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - initial scrutiny letter
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - initial scrutiny letter (PDF 94 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - response to initial scrutiny
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - response to initial scrutiny (PDF 267 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - final scrutiny letter
Colorectal cancer (metastatic) - aflibercept: Sanofi appeal - final scrutiny letter (PDF 142 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal information
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - appeal letter
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - appeal letter (PDF 44 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - initial scrutiny letter
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - initial scrutiny letter (PDF 37 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - final scrutiny letter
Colorectal cancer (metastatic) - aflibercept: Beating Bowel Cancer appeal - final scrutiny letter (PDF 18 KB)

Published:

23 January 2014
Colorectal cancer (metastatic) - aflibercept: register to attend the appeal information
Colorectal cancer (metastatic) - aflibercept: notice of appeal information

Colorectal cancer (metastatic) - aflibercept: appraisal consultation

Colorectal cancer (metastatic) - aflibercept: appraisal consultation
Colorectal cancer (metastatic) - aflibercept: appraisal consultation document information
Colorectal cancer (metastatic) - aflibercept: evaluation report information
Colorectal cancer (metastatic) - aflibercept: evaluation report (PDF 4.99 MB)

Published:

21 June 2013
Evidence Review Group report - Erratum
Evidence Review Group report - Erratum (PDF 72 KB)

Published:

21 August 2013

Colorectal cancer (metastatic) - aflibercept: Appendix C - final scope

Colorectal cancer (metastatic) - aflibercept: Appendix C - final scope
Colorectal cancer (metastatic) - aflibercept: Appendix C - final scope (PDF 27 KB)

Published:

02 January 2013

Colorectal cancer (metastatic) - aflibercept: Appendix B - final matrix

Colorectal cancer (metastatic) - aflibercept: Appendix B - final matrix
Colorectal cancer (metastatic) - aflibercept: Appendix B - final matrix (PDF 36 KB)

Published:

02 January 2013

Colorectal cancer (metastatic) - aflibercept: Appendix D - response to comments on the draft scope and provisional matrix

Colorectal cancer (metastatic) - aflibercept: Appendix D - response to comments on the draft scope and provisional matrix
Colorectal cancer (metastatic) - aflibercept: Appendix D - response to comments on the draft scope and provisional matrix (PDF 93 KB)

Published:

02 January 2013

Colorectal cancer (metastatic) - aflibercept: Appendix B - draft scope for consultation (pre-referral) - September 2011

Colorectal cancer (metastatic) - aflibercept: Appendix B - draft scope for consultation (pre-referral) - September 2011
Colorectal cancer (metastatic) - aflibercept: Appendix B - draft scope for consultation (pre-referral) - September 2011 (PDF 103 KB)

Published:

21 March 2012

Colorectal cancer (metastatic) - aflibercept: Appendix C - provisional matrix (pre-referral) - September 2011

Colorectal cancer (metastatic) - aflibercept: Appendix C - provisional matrix (pre-referral) - September 2011
Colorectal cancer (metastatic) - aflibercept: Appendix C - provisional matrix (pre-referral) - September 2011 (PDF 106 KB)

Published:

21 March 2012